Alendronate and hormone replacement therapy in the prevention of osteoporotic fracture: a pharmacoeconomic analysis employing a net-benefit regression method of cost-effectiveness

Simple item page
dc.contributor.advisorRascati, Karen L.en
dc.contributor.advisorWilson, James P.en
dc.creatorTiller, Kevin Wadeen
dc.date.accessioned2008-08-28T21:53:45Zen
dc.date.accessioned2017-05-11T22:16:20Z
dc.date.available2008-08-28T21:53:45Zen
dc.date.available2017-05-11T22:16:20Z
dc.date.issued2004en
dc.descriptiontexten
dc.description.departmentPharmacyen
dc.format.mediumelectronicen
dc.identifierb59058742en
dc.identifier.oclc57663420en
dc.identifier.proqst3143479en
dc.identifier.urihttp://hdl.handle.net/2152/1271en
dc.language.isoengen
dc.rightsCopyright is held by the author. Presentation of this material on the Libraries' web site by University Libraries, The University of Texas at Austin was made possible under a limited license grant from the author who has retained all copyrights in the works.en
dc.subject.lcshOsteoporosis in women--Treatment--Cost effectivenessen
dc.subject.lcshOsteoporosis in women--Prevention--Cost effectivenessen
dc.subject.lcshOsteoporosis in women--Treatmenten
dc.subject.lcshOsteoporosis in women--Risk factorsen
dc.subject.lcshOsteoporosis in women--Epidemiologyen
dc.subject.lcshOsteoporosis in women--Hormone therapy--Cost effectivenessen
dc.subject.lcshOsteoporosis in women--Hormone therapyen
dc.titleAlendronate and hormone replacement therapy in the prevention of osteoporotic fracture: a pharmacoeconomic analysis employing a net-benefit regression method of cost-effectivenessen
dc.type.genreThesisen

Files

Collections

University of Texas at Austin